Selective Inhibitors of Histone Deacetylase 10 (HDAC-10)

Area of Science:

• Epigenetics and molecular biology
• Medicinal chemistry and drug discovery
• Oncology

Background:

• Histone acetylation balance is a key epigenetic regulator of gene expression implicated in disease progression.
• Histone deacetylase 10 (HDAC-10) overexpression is linked to chemotherapy resistance and poor outcomes in aggressive solid tumors, notably neuroblastoma.
• Selective HDAC-10 inhibition shows potential for improved therapeutic profiles by suppressing autophagic response.

Purpose of the Study:

• To review novel selective or dual HDAC-8/10 inhibitors as potential next-generation cancer chemotherapy agents.
• To identify new drug leads that avoid the severe side effects associated with current broad-spectrum HDAC inhibitors.
• To explore structural requirements for potent and selective HDAC-10 inhibition.

Main Methods:

• Literature search of MedLine, PubMed, Caplus, and SciFinder Scholar databases (2015-present).
• Analysis of synthesized tricyclic and bicyclic HDAC inhibitor analogues based on Tubastatin A.
• Evaluation of dual HDAC-8/10 inhibitors, including hydroxamic acid TH34 and hybrid derivatives.

Main Results:

• Compound 36 demonstrated a strong pharmacological profile with high potency against HDAC-10 (pIC50 = 8.4) and selectivity over Class I HDACs.
• Dual inhibitors TH34, 46d, 46e, and 46g showed promising potency and selectivity for HDAC-8 and HDAC-10.
• Key structural interactions for HDAC-10 inhibition include electrostatic and hydrogen bond interactions with E274 and complementarity to the P(E,A) CE motif helix.

Conclusions:

• HDAC-10 is a promising therapeutic target for cancer chemotherapy, particularly in overcoming drug resistance.
• Selective or dual HDAC-8/10 inhibitors represent a new class of anticancer agents with potential for reduced toxicity.
• Understanding structural requirements is crucial for designing effective and selective HDAC inhibitors for neuroblastoma and other aggressive solid tumors.